Announcements Trials
Browse Landscape

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Breast 6Gastrointestinal 3Tumor-Agnostic 2Thoracic 2CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Acceptance and Commitment Therapy × Tumor-Agnostic × Clear all
NCT03910296 2022-05-03

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Dana-Farber Cancer Institute

Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04636346 2020-12-17

COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF

University of California, San Francisco

Completed
129 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡